Document:

EX-10.2

 Exhibit 10.2 
 SPECTRUM PHARMACEUTICALS, INC. 
 TERM SHEET FOR 2009 INCENTIVE AWARD PLAN

 NONQUALIFIED STOCK OPTION AWARD 
 AWARDED TO NON-EMPLOYEE DIRECTORS 
 FOR GOOD AND VALUABLE CONSIDERATION, Spectrum
Pharmaceuticals, Inc. (the “Company”), hereby grants to the Participant named below a nonqualified stock option (the “Option”) to purchase any part or all of the number of shares of its common stock (the “Common
Stock”), that are covered by this Option, as specified below, at the Exercise Price per share specified below and upon the terms and subject to the conditions set forth in this Term Sheet, the Spectrum Pharmaceuticals, Inc. 2009 Incentive Award
Plan (the “Plan”) and the Standard Terms and Conditions (the “Standard Terms and Conditions”) promulgated under such Plan, each as amended from time to time. This Option is granted pursuant to the Plan and is subject to and
qualified in its entirety by the Standard Terms and Conditions. 
  

					
	 Name of Participant:
	  			
	 Grant Date:
	  			
	 Number of Shares of Common Stock covered by Option:
	  			
	 Exercise Price Per Share:
	  	$	            	  
	 Vesting Schedule:
	  			

 This Option is not intended to qualify as an incentive stock option under Section 422 of the Internal Revenue Code
of 1986, as amended. By accepting this Term Sheet, Participant acknowledges that he or she has received and read, and agrees that this Option shall be subject to, and Participant shall comply with, the terms of this Term Sheet, the Plan and the
Standard Terms and Conditions. 
 IN WITNESS WHEREOF, the Company has caused this Option to be executed by its duly authorized officer.

  

	
	 SPECTRUM PHARMACEUTIALS, INC.

	
	 

	 Rajesh C. Shrotriya, M.D.

	 CEO & President

 [Participant/Spouse Signature page follows on the reverse side of this Term Sheet]

 PARTICIPANT’S ACCEPTANCE 

The undersigned hereby accepts the foregoing Option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges that a copy of
the Standard Terms and Conditions and the Plan are available on the Company’s intranet. 
  

	
	PARTICIPANT
	
	  

	Signature

 By his or her signature below, the spouse of the Participant, if Participant is legally married as of the date of
his or her execution of this Term Sheet, acknowledges that he or she has read this Term Sheet, the Standard Terms and Conditions and the Plan and is familiar with the terms and provisions thereof, and agrees to be bound by all the terms and
conditions of this Term Sheet, the Standard Terms and Conditions and the Plan. 
  

	
	
	  

	 Signature of Spouse

 OR 
 By his or her signature below, the Participant represents that he or she is not legally married as of the date of execution of this Term Sheet. 

 

	
	 PARTICIPANT

	
	  

	 Signature

 SPECTRUM PHARMACEUTICALS, INC. 

STANDARD TERMS AND CONDITIONS FOR 
 NONQUALIFIED STOCK OPTION AWARD 
 GRANTED TO NON-EMPLOYEE DIRECTORS

 These Standard Terms and Conditions apply to any Options granted under the Spectrum Pharmaceuticals, Inc. 2009 Incentive Award Plan (the
“Plan”) to non-employee members of the Company’s Board of Directors, which are identified as nonqualified stock options and are evidenced by a Term Sheet or an action of the Administrator that specifically refers to these Standard
Terms and Conditions. Capitalized terms not otherwise defined herein shall have the meaning set forth in the Plan. 
  

	1.	TERMS OF OPTION 

 SPECTRUM
PHARMACEUTICALS, INC. (the “Company”), has granted to the Participant named in the Term Sheet provided to said Participant herewith (the “Term Sheet”) a nonqualified stock option (the “Option”) to purchase up to the
number of shares of the Company’s common stock (the “Common Stock”), set forth in the Term Sheet, at the purchase price per share and upon the other terms and subject to the conditions set forth in the Term Sheet, these Standard Terms
and Conditions (as amended from time to time), and the Plan. For purposes of these Standard Terms and Conditions and the Term Sheet, any reference to the Company shall include a reference to any Subsidiary. 

 

	2.	NON-QUALIFIED STOCK OPTION 

The Option is not intended to be an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended (the
“Code”) and will be interpreted accordingly. 
  

	3.	EXERCISE OF OPTION 

 The
Option shall continue to vest, in accordance with the Vesting Schedule set forth on the Term Sheet, so long as Participant remains in Continuous Service. Participant may exercise any vested portion of the Option at any time prior to the Expiration
Date of the Option. 
 To exercise the Option (or any part thereof), Participant shall provide notice to the Company specifying
the number of whole shares of Common Stock Participant wishes to purchase and how Participant’s shares of Common Stock should be registered (in Participant’s name only or in Participant’s and Participant’s spouse’s names as
community property or as joint tenants with right of survivorship). 
 The exercise price (the “Exercise Price”) of the
Option is set forth in the Term Sheet. The Company shall not be obligated to issue any shares of Common Stock until Participant shall have paid the total Exercise Price for that number of shares of Common Stock. The Exercise Price may be paid as
permitted in the Plan. 
 Fractional shares will not be issued. Shares of Common Stock will be issued as soon as practical after
exercise. Notwithstanding the above, the Company shall not be obligated to deliver any shares of Common Stock during any period when the Company determines that the exercisability of the Option or the delivery of shares hereunder would violate any
federal, state or other applicable laws. 
  

	4.	EXPIRATION OF OPTION 

 The
Option shall expire and cease to be exercisable ten (10) years after the Grant Date of the Option (the Expiration Date), except as provided in this Section 4. 
  

	 	A.	This Option shall expire and cease to be exercisable upon the earlier of the Expiration Date of the Option or the expiration of five (5) years from the date
of termination of Participant’s Continuous Service if such termination occurs for any reason other than (i) removal from office by action of the Board or the stockholders of the Company, or (ii) a failure to be elected as a director
by the stockholders at any meeting of the stockholders at which Participant was a candidate for election to the Board, or (iii) Participant resigning from the Board prior to the expiration of his or her term of office. 

	 	B.	This Option shall expire and cease to be exercisable upon the earlier of the Expiration Date of the Option or the expiration of three (3) months from the
date of termination of Participant’s Continuous Service if such termination is due to (i) removal from office by action of the Board or the stockholders of the Company, or (ii) a failure to be elected as a director by the stockholders
at any meeting of the stockholders at which Participant was a candidate for election to the Board, or (iii) Participant resigning from the Board prior to the expiration of his or her term of office. 

 

	5.	RESTRICTIONS ON RESALES OF OPTION SHARES 

 The Company may impose such restrictions, conditions or limitations as it determines appropriate as to the timing and manner of any resales by the Participant or other subsequent transfers by the
Participant of any shares of Common Stock issued as a result of the exercise of the Option, including without limitation (a) restrictions under an insider trading policy, (b) restrictions designed to delay and/or coordinate the timing and
manner of sales by Participant and other optionholders, (c) restrictions as to the use of a specified brokerage firm for such resales or other transfers or (d) restrictions under federal or state securities laws. 

 

	6.	INCOME TAXES 

 To the
extent required by applicable federal, state, local or foreign law, the Participant shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise by reason of an Option exercise or disposition
of shares issued as a result of an Option exercise. The Company shall not be required to issue shares or to recognize the disposition of such shares until such obligations are satisfied. 

 

	7.	NON-TRANSFERABILITY OF OPTION 

 The Participant may transfer some or all of his or her Options to one or more “family members,” which is not a “prohibited transfer for value,” provided that (i) the Participant
(or such Participant’s estate or representative) shall remain obligated to satisfy all income or other tax withholding obligations associated with the exercise of such Option; (ii) the Participant shall notify the Company in writing that
such transfer has occurred and disclose to the Company the name and address of the “family member” or “family members” and their relationship to the Participant, and (iii) such transfer shall be effected pursuant to transfer
documents in a form approved by the Committee. For purposes of the foregoing, the terms “family members” and “prohibited transfer for value” have the meaning ascribed to them in the General Instructions to form S-8 (or any
successor form) promulgated under the Securities Act of 1933, as amended. 
  

	8.	THE PLAN AND OTHER AGREEMENTS 

 In addition to these Standard Terms and Conditions, the Option shall be subject to the terms of the Plan, which are incorporated into these Standard Terms and Conditions by this reference. A copy of the
Plan, and the accompanying prospectus, is available at the Company’s intranet site. 
 The Term Sheet, these Standard Terms
and Conditions and the Plan constitute the entire understanding between the Participant and the Company regarding the Option. Any prior agreements, commitments or negotiations concerning the Option are superseded. 

	9.	LIMITATION OF INTEREST IN SHARES SUBJECT TO OPTION 

 Neither the Participant (individually or as a member of a group) nor any beneficiary or other person claiming under or through the Participant shall have any right, title, interest, or privilege in or to
any shares of Common Stock allocated or reserved for the purpose of the Plan or subject to the Term Sheet or these Standard Terms and Conditions except as to such shares of Common Stock, if any, as shall have been issued to such person upon exercise
of the Option or any part of it. Nothing in the Plan, in the Term Sheet, these Standard Terms and Conditions or any other instrument executed pursuant to the Plan shall confer upon the Participant any employment rights or any rights to continue as a
director with the Board or in service to the Company. 
  

	10.	DEFINITIONS 

 For purposes
of these Standard Terms and Conditions, “Continuous Service” means (i) employment by either the Company or any subsidiary, or by a corporation or a parent or subsidiary of a corporation issuing or assuming a stock option in a
transaction to which Section 424(a) of the Code applies, which is uninterrupted except for vacations, illness (except for Disability), or leaves of absence which are approved in writing by the Company or such other employer corporation (and in
the case of an incentive stock option, the leave of absence cannot exceed 90 days unless reemployment following the leave is guaranteed by contract or statute), (ii) service as a member of the Board until Participant dies, resigns, is
removed from office, or Participant’s term of office expires and he or she is not reelected, or (iii) so long as Participant is engaged as Service Provider to the Company or other corporation referred to in clause (i) above.

  

	11.	GENERAL 

 In the event
that any provision of these Standard Terms and Conditions is declared to be illegal, invalid or otherwise unenforceable by a court of competent jurisdiction, such provision shall be reformed, if possible, to the extent necessary to render it legal,
valid and enforceable, or otherwise deleted, and the remainder of these Standard Terms and Conditions shall not be affected except to the extent necessary to reform or delete such illegal, invalid or unenforceable provision. 

The headings preceding the text of the sections hereof are inserted solely for convenience of reference, and shall not constitute a part
of these Standard Terms and Conditions, nor shall they affect its meaning, construction or effect. 
 These Standard Terms and
Conditions shall inure to the benefit of and be binding upon the parties hereto and their respective permitted heirs, beneficiaries, successors and assigns. 
 All questions arising under the Plan or under these Standard Terms and Conditions shall be decided by the Administrator in its sole and absolute discretion. 

 

	12.	“MARKET STAND-OFF” CONDITIONS 

 Participant agrees that, if requested by the Company, Participant will not sell or otherwise transfer or dispose of any shares held by Participant without the prior written consent of the Company during
such period of time. 
  

	13.	INTERPRETATION 

 This
Option is granted pursuant to the terms of the Plan, and shall in all respects be interpreted in accordance therewith. The Committee shall have the power to interpret the Plan, the Term Sheet and these Standard Terms and Conditions and to adopt such
rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules. Any action, decision, interpretation or determination by the Committee shall be final, binding and
conclusive on the Company and the Participant. No member of the Committee shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or the Option. Notwithstanding the provision of
Sections 10.1(a) — 10.1(d) of the Plan, the Committee shall have the discretion to provide terms and conditions regarding (i) the vesting of this Option in the event of a Change in Control, and/or (ii) the assumption of this
Option or issuance of comparable securities or new incentives in the event of a Change in Control. 

	14.	NOTICES 

 Any notice,
demand or request required or permitted to be given under the Term Sheet and these Standard Terms and Conditions shall be in writing and shall be deemed given when delivered personally or three (3) days after being deposited in the United
States mail, as certified or registered mail, with postage prepaid, and addressed, if to the Company, at its principal place of business, Attention: Legal Department, and if to the Participant, at his or her most recent address as shown in the
employment or stock records of the Company. 
  

	15.	GOVERNING LAW 

 The
validity, construction, interpretation, and effect of this Option shall be governed by and determined in accordance with the laws of the State of California. 
  

	16.	SEVERABILITY 

 Should any
provision or portions of this Agreement be held to be unenforceable or invalid for any reason, the remaining provisions and portions of this Agreement shall be unaffected by such holding. 

 

	17.	COUNTERSIGNATURE 

 The
Term Sheet may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall be deemed one instrument, and is incorporated herein.EX-10.8

 Exhibit 10.8 
 LICENSE AGREEMENT 
 THIS LICENSE AGREEMENT (this
“Agreement”), dated as of December 21, 2007 (the “Effective Date”), is made by and between CELL THERAPEUTICS, INC., a Washington corporation (“CTI”), and BIOGEN IDEC INC., a Delaware corporation (“BIIB”).

 WHEREAS, pursuant to that certain Asset Purchase Agreement, dated as of August 15, 2007, by and between CTI and BIIB
(the “Asset Purchase Agreement”), CTI has purchased certain assets (the “Acquisition”) from BIIB relating to the Product (as defined in the Asset Purchase Agreement); and 

WHEREAS, in connection with the Acquisition, BIIB desires to grant, and CTI desires to accept, certain licenses to the Licensed Patents
(as defined in the Asset Purchase Agreement), all the terms and subject to the conditions set forth in this Agreement. 
 NOW,
THEREFORE, in consideration of the premises and mutual covenants contained herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, CTI and BIIB agree as follows: 

ARTICLE I 

DEFINITIONS 
 Section 1.1 Definitions. As used in this Agreement, the following terms shall have the meanings ascribed to them below (note: terms used but not otherwise defined herein shall have their
respective meanings as set forth in the Asset Purchase Agreement): 
 “Action” means any claim, dispute, action
(including any action seeking injunctive or other equitable relief), arbitration, mediation, litigation, proceeding, suit or governmental investigation and any appeal therefrom. 

“Acquisition” has the meaning set forth in the recitals. 

“Affiliate” means, with respect to any Person, any other Person that directly or indirectly Controls, is Controlled by or is
under common Control with such first person. A Person will be deemed to “Control” another Person if such first person has the power to direct or cause the direction of the management and policies of such other Person, whether through
ownership of securities, by contract or otherwise. 
 “Agreement” has the meaning set forth in the introductory
paragraph. 
 “Asset Purchase Agreement” has the meaning set forth in the recitals. 

“BIIB” has the meaning set forth in the introductory paragraph. 

“Cabilly Agreement” means that certain Amended and Restated Non-Exclusive License Agreement, dated on or about the date hereof,
by and between Genentech and BIIB, as may be amended from time to time. 

 “Cross-License Patents” means any patents that (i) are assigned or licensed
(or are based upon patent applications assigned or licensed) by BIIB to CTI pursuant to the Transaction Documents and (ii) were granted, or are based upon patent applications that were pending, as of December 7, 1993. 

“CTI” has the meaning set forth in the introductory paragraph. 

“Effective Date” means the meaning set forth in the introductory paragraph. 

“Genentech” means Genentech, Inc., a Delaware corporation. 

“Governmental Entity” means any court, administrative agency or commission or other governmental or regulatory authority or
instrumentality of applicable jurisdiction, whether domestic or foreign. 
 “Licensed Patents” has the meaning set
forth in the Asset Purchase Agreement. 
 “Person” means any individual, corporation, partnership, limited liability
company, joint venture, trust, business association, organization, Governmental Entity or other entity. 
 “Product”
has the meaning set forth in the Asset Purchase Agreement. 
 “Term” has the meaning set forth in Section 4.1.

 “Transaction Documents” has the meaning set forth in the Asset Purchase Agreement. 

“United States” means the United States of America, together with all of its territories and possessions, and the Commonwealth
of Puerto Rico. 
 Section 1.2 Interpretation. 

(a) When used in this Agreement, the words “include,” “includes” and “including” shall be deemed to be
followed by the words “without limitation.” 
 (b) Any terms defined in the singular shall have a comparable meaning
when used in the plural, and vice-versa. 
 (c) All references to any introductory paragraph, recitals, Articles, Sections,
Exhibits and Schedules shall be deemed references to the introductory paragraph, recitals, Articles, Sections, Exhibits and Schedules to this Agreement unless otherwise specifically set forth herein. 

(d) This Agreement shall be deemed drafted jointly by CTI and BIIB and shall not be specifically construed against either party based on
any claim that such party or its counsel drafted this Agreement. 

  
 2 

 ARTICLE II 
 LICENSE 
 Section 2.1 License. Subject to the terms and
conditions of this Agreement, BIIB hereby grants to CTI, and CTI hereby accepts, an exclusive (even as to BIIB but subject to the license to Genentech contemplated by Section 2.2), fully-paid, freely transferable (including the right to
sublicense) license under the Licensed Patents to develop, make, have made, use, offer to sell, sell, have sold and import the Product in the United States during the Term, but solely for ultimate use of such Product by end-users in the United
States. For the avoidance of doubt, no rights are granted pursuant to this Agreement (and CTI shall have no rights) with respect to the Licensed Patents (i) for any purpose other than to develop, make, have made, use, offer to sell, sell, have
sold and import the Product in the United States during the Term for ultimate use of such Product by end-users in the United States or (ii) for any purpose in any territory outside of the United States even if such purpose results in ultimate
use of such Product by end-users in the United States. The foregoing restrictions pertaining to use by end-users (in the preceding sentence) shall not be construed to prevent the sale of the Product to Persons in a distribution chain resulting in
eventual use by end-users in the United States. 
 Section 2.2 Reservation of Cross-License for Genentech. The
license granted herein pursuant to Section 2.1(a) is subject to BIIB’s non-exclusive license to Genentech to make, use and sell the Product within the Field (as defined in the Cabilly Agreement) and in the United States under any
Cross-License Patents that would otherwise block the ability of Genentech or its Designee (as defined in the Cabilly Agreement) to make, use or sell the Product within the Field and in the United States. 

Section 2.3 Prosecution, Maintenance and Enforcement. As between the parties: (i) BIIB shall have the sole right, to be
exercised (or not exercised) in BIIB’s sole discretion, as to (x) the prosecution and maintenance of the Licensed Patents and (y) the conduct of any and all Actions in respect of any infringement of any of the Licensed Patents; and
(ii) BIIB shall bear the cost of any such prosecution, maintenance and Actions; provided, however, that (A) CTI shall, as reasonably requested by BIIB, provide reasonable cooperation and assistance to BIIB in relation to any
such prosecution, maintenance and Actions insofar as the same shall relate to the Product, all at the expense of BIIB, and (B) BIIB shall (subject to any relevant confidentiality obligations of BIIB) consult with CTI to the extent that any such
prosecution or maintenance, or the conduct of any such Actions, could reasonably be expected to have any material effect on the Product. CTI and BIIB shall each inform the other promptly in writing of any alleged infringement by a third Person of
the Licensed Patents that comes to its attention and of any reasonably available evidence thereof. All recoveries by BIIB from Actions (net of reasonable fees and expenses, including reasonable attorneys’ fees and costs) shall be treated as
part of the Yearly Net Sales Amount (as defined in the Asset Purchase Agreement) to the extent attributable or allocable solely to the Product in the United States and such amounts shall be promptly paid to CTI. 

ARTICLE III  
 REPRESENTATIONS AND WARRANTIES 
 Section 3.1 BIIB. BIIB
represents and warrants to CTI, as of the Effective Date, as follows: 
  

	 	(a)	BIIB has the power and authority to execute, deliver and perform this Agreement, and this Agreement is a valid and binding obligation of BIIB, enforceable in accordance
with its terms; and 

  

	 	(b)	BIIB has the right to grant the licenses to the Licensed Patents that are the subject of this Agreement. 

  
 3 

 Section 3.2 No Implied Warranties. EXCEPT AS EXPRESSLY SET FORTH ABOVE IN
SECTION 3.1 AND IN ARTICLE V OF THE ASSET PURCHASE AGREEMENT, BIIB MAKES NO WARRANTIES OR REPRESENTATIONS, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY, VALIDITY, ENFORCEABILITY OR
NON-INFRINGEMENT REGARDING OR WITH RESPECT TO THE LICENSED PATENTS. 
 ARTICLE IV 

TERM AND TERMINATION 
 Section 4.1 Term. This Agreement shall commence on the Effective Date and shall continue until the last to expire of the Licensed Patents, unless earlier terminated in accordance with this
Article IV (the “Term”). 
 Section 4.2 Termination. 

(a) BIIB and CTI shall each have the right to terminate this Agreement with immediate effect upon written notice to the other upon the
occurrence of any of the following: 
 (i) the other party files a petition in bankruptcy, or enters into an
agreement with its creditors, or applies for or consents to the appointment of a receiver or trustee, or makes an assignment for the benefit of creditors, or becomes subject to involuntary proceedings under any bankruptcy or insolvency law; or

 (ii) the other party fails to cure any material noncompliance with any of the terms and conditions hereof or
any material breach of the representations and warranties hereof within the time period specified in any written notice (which shall be at least sixty (60) days) delivered to such non-compliant or breaching party. 

(b) CTI shall have the additional right to terminate this Agreement without cause upon written notice delivered to BIIB. 

(c) BIIB shall have the additional right to terminate this Agreement with immediate effect upon written notice to CTI upon CTI failing to
cure any material noncompliance with any of the terms and conditions of any of the Transaction Documents within the time period specified in any written notice (which shall be at least sixty (60) days) delivered to CTI; provided,
however, that the foregoing shall not apply to any such non-compliance relating solely to a good faith payment dispute so long as such dispute remains unsettled and any amounts not in dispute have been timely paid. 

Section 4.3 Effect of Termination. If this Agreement expires pursuant to Section 4.1 or is terminated pursuant to
Section 4.2, any such expiration or termination shall not operate to discharge any liability that had been incurred by either party prior thereto. 
 Section 4.4 Survival. Sections 2.3, 3.2 and 4.3 and Article V shall survive any expiration or termination of this Agreement. 

  
 4 

 ARTICLE V 
 MISCELLANEOUS 
 The provisions of Articles XII (Indemnification) and
XIII (General Provisions) of the Asset Purchase Agreement are incorporated herein, mutatis mutandis, by reference and shall be effective as if fully set forth herein. In furtherance of the foregoing, consistent with
Section 12.2 of the Asset Purchase Agreement, each party acknowledges and agrees that the other party shall be entitled to seek temporary or permanent injunctive relief or specific performance in order to enforce its rights under this
Agreement. 
 [SIGNATURE PAGE FOLLOWS] 

  
 5 

 IN WITNESS WHEREOF, the parties have caused this License Agreement to be signed by their
respective representatives thereunto duly authorized, all as of the Effective Date. 
  

			
	BIOGEN IDEC INC.
		
	By:	 	 /s/ Faheem Hasnain

		 	Name:
		 	Title:
	
	CELL THERAPEUTICS, INC.
		
	By:	 	 /s/ James A. Bianco

		 	Name:
		 	Title:

  
 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00209-of-00352.parquet"}]]